Ken Griffin Renovo Rx, Inc. Call Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RNXT
# of Institutions
18Shares Held
1.87MCall Options Held
0Put Options Held
0-
Bank Of The West975KShares$994,5000.27% of portfolio
-
Adar1 Capital Management, LLC Austin, TX355KShares$362,3440.08% of portfolio
-
Geode Capital Management, LLC Boston, MA144KShares$146,7970.0% of portfolio
-
Nixon Peabody Trust CO Boston, MA97.2KShares$99,1080.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny86.3KShares$88,0420.0% of portfolio
About RenovoRx, Inc.
- Ticker RNXT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 9,066,860
- Market Cap $9.25M
- Description
- RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...